During a live event, Christine Bestvina, MD, discussed trials of KRAS inhibitors plus immunotherapy in patients with ...

These data support the use of sacituzumab plus pembrolizumab as a potential new standard of care,” said Sara Tolaney, MD.

Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

Pembrolizumab, an anti-programmed death receptor-1 (PD-1) therapy, is currently approved under the brand name Keytruda ® for other gynecological cancers, including cervical cancer and endometrial ...

Pembrolizumab is also approved as first-line treatment in cisplatin-ineligible patients with high PD-L1 expression. 9-11 Integrating short courses of pre-RC immunotherapy in nonmetastatic MIBC has the ...

Pembrolizumab conferred a small but statistically significant survival benefit when added to best supportive care as second-line treatment for patients with advanced hepatocellular carcinoma ...

Pembrolizumab is an anti–PD-1 monoclonal antibody that has shown promising efficacy and manageable safety as monotherapy in patients with cervical cancer. 1,2 The phase III KEYNOTE-826 study evaluated ...

The addition of pembrolizumab to chemotherapy improved OS, PFS and objective response rates among patients with untreated, advanced esophageal and esophagogastric junction adenocarcinoma, results ...

BARCELONA, Spain — Adding pembrolizumab to standard concurrent chemoradiotherapy (CCRT) significantly improves overall survival in patients with high-risk, locally advanced cervical cancer ...

So I'm happy to share with you the results from the study combining pembrolizumab and regorafenib in second-line treatment of hepatocellular carcinoma after treatment with immune checkpoint ...

The addition of pembrolizumab to standard platinum-pemetrexed chemotherapy results in significant improvement in overall survival among patients with advanced pleural mesothelioma, according to a ...